Moxifloxacin Stada®

Moxifloxacin, the active ingredient in Moxifloxacin Stada®, is a fluoroquinolone antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and skin and soft‑tissue infections in adult patients.

GNH USA supplies Moxifloxacin Stada® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone that targets bacterial DNA replication in respiratory and skin infections. - Community‑acquired pneumonia: eradicates causative bacteria, facilitating clinical recovery. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms. - Acute bacterial exacerbation of chronic bronchitis: improves lung function by clearing bacterial load. - Skin and soft‑tissue infections: resolves infection and promotes wound healing.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Rash: mild skin erythema. - Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, especially in the Achilles. - QT interval prolongation: cardiac rhythm disturbances. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - Peripheral neuropathy: numbness or tingling in extremities. - Hepatotoxicity: significant liver injury with jaundice.

Before prescribing Moxifloxacin, clinicians should assess patient history and potential risks. - Assess cardiac history: avoid in patients with known QT prolongation. - Review tendon health: caution in those with recent tendon injury or steroid use. - Evaluate renal function: dose adjustment may be required in severe impairment. - Monitor for hypersensitivity: discontinue if severe allergic reactions occur. - Avoid in pregnancy and lactation unless benefits outweigh risks: safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Moxifloxacin can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption, separate dosing by at least 2 hours. - Warfarin: may increase INR, requiring close monitoring. - Drugs that prolong QT interval (e.g., macrolides, fluoroquinolones): heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase plasma levels. - Theophylline: potential for increased theophylline toxicity. - Corticosteroids: may raise risk of tendon rupture. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of central nervous system effects.